Nervonik, a medical device company focused on opioid-free chronic pain solutions, has raised $13 million in Series A financing. The funding round was led by U.S. Venture Partners (USVP), with additional participation from Foothill Ventures, Correlation Ventures, and other investors.
This latest round follows earlier investments, including $4.4 million in SAFE and convertible note financing from investors such as Shangbay Capital, Camford Capital, Joyance Partners, Life Science Angels, and Seraph Group. The company’s valuation was not disclosed.
With over 50 million Americans suffering from chronic pain, the demand for effective, opioid-free treatments is higher than ever. Nervonik’s peripheral nerve stimulation (PNS) technology is designed to provide minimally invasive, patient-friendly relief, positioning the company in a rapidly growing medtech market.
Aydin Babakhani, PhD, Nervonik’s founder and CEO, highlighted the significance of this funding: “We are excited to receive this strong support from top institutional investors as we push forward in advancing peripheral nerve stimulation technology.”
Nervonik will use the Series A funds to expand clinical trials, pursue regulatory clearances, and lay the groundwork for commercialization. The goal is to accelerate market entry and expand access to its innovative therapy, offering a meaningful alternative to traditional pain management.
The company’s immediate focus is to build on the success of its first-in-human clinical study, which demonstrated the potential of its proprietary wireless PNS technology in delivering personalized pain relief.
Founded by Aydin Babakhani, PhD, Nervonik is a medical device innovator dedicated to redefining chronic pain treatment through advanced peripheral nerve stimulation. Its proprietary system uses wireless power and closed-loop sensing, allowing for a less invasive, more adaptable therapy that can be tailored to each patient.
The company’s leadership team includes experts in neurotechnology, medical devices, and healthcare commercialization, all united by a mission to improve quality of life for millions.
Nervonik’s Series A follows earlier funding from a diverse group of healthcare and technology investors, including:
The involvement of U.S. Venture Partners (USVP) in this round underscores Nervonik’s long-term potential in the medtech innovation landscape. USVP’s portfolio spans over 500 companies, including Inari Medical, Inspire Medical Systems, and Intersect ENT, highlighting their deep expertise in healthcare technology investments.
